A synthetic factor-Xa inhibitor (ORG31540/SR9017A) as an adjunct to fibrinolysis in acute myocardial infarction: The Pentalyse study

European Heart Journal

Volumn 22, Issue 18, 2001, Pages 1716-1724

  Coussement, P K ^a   Bassand, J P ^b   Convens, C ^c   Vrolix, M ^d   Boland, J ^e   Grollier, G ^f   Michels, R ^g   Vahanian, A ^h   Vanderheyden, M ⁱ   Rupprecht, H J ^j   Van De Werf, Frans ^a,k  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b HÔPITAL SAINT JACQUES   (France)

^c MIDDELHEIM HOSPITAL   (Belgium)

^d ZOL Campus St Jan ^*  (Belgium)

^e Regional Hospital Centre La Citadelle   (Belgium)

^f CAEN UNIVERSITY HOSPITAL   (France)

^g CATHARINA HOSPITAL   (Netherlands)

^h HÔPITAL TENON   (France)

ⁱ IMELDA HOSPITAL   (Belgium)

^j UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^k UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

Fibrinolysis; Heparin; Myocardial infarction; Reperfusion

Indexed keywords

FONDAPARINUX; HEPARIN; THROMBIN ANTITHROMBIN COMPLEX;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANTITHROMBIN III; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; EUROPE; FEMALE; FIBRINOLYSIS; FOLLOW-UP STUDIES; HEPARIN; HUMANS; INCIDENCE; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PEPTIDE HYDROLASES; RECURRENCE; SERINE PROTEINASE INHIBITORS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0034822182     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2777     Document Type: Article

References (27)

1. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: Results of a randomized double blind European Cooperative Study Group trial
2. In-hospital mortality and clinical course of 20891 patients with suspected acute myocardial infarction randomized between alteplase and streptokinase with or without heparin
3. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients
4. Heparin
5. SR 90107A/Org 31540, a novel anti-factor Xa antithrombotic agent
6. Biochemical and pharmacological rationale for the development of a synthetic heparin pentasaccharide
7. Free factor Xa is on the main pathway of thrombin generation in clotting plasma
8. Inhibition of the early stages of the thrombin generation reaction by various glycosaminoglycans
9. Pentasaccharide and Orgaran™ arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt
10. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107A/ORG31540) with high affinity to antithrombin III in man
11. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement
12. The Ephesus Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
13. The Pentamaks Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thrombo embolism (VTE) after elective major knee surgery
14. The Penthifra Study. Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin (LMWH) in the prevention of venous thrombo embolism (VTE) after hip fracture surgery
15. The Pentathlon 2000 Study: Comparison of the first synthetic factor Xa inhibitor with low molecular weight heparin in the prevention of venous thrombo embolism (VTE) after elective hip replacement surgery
16. Efficacy of a synthetic pentasaccharide, a pure factor Xa inhibitor, as an antithrombotic agent. A pilot study in the setting of coronary angioplasty
17. Comparison of a synthetic antithrombin III-binding pentasaccharide and standard heparin as an adjunct to coronary thrombolysis
18. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase
19. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
20. The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction
21. Thrombolysis in Myocardial Infarction (TIMI) Trial Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
22. Fifth ACCP Consensus Conference on Antithrombotic Therapy. Coronary thrombolysis
23. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction
24. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction
25. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction
26. A randomized comparison of low-molecular-weight heparin and unfractionated heparin adjunctive to t-PA thrombolysis and aspirin (HART-II)
27. The ASSENT-Plus Study. A comparison of dalteparin and unfractionated heparin as adjunct to t-PA